Erythropoietin, folic acid deficiency and hyperhomocysteinemia: Is there a possible relationship in chronically hemodialyzed patients?

Clinical Nephrology

Volumn 53, Issue 1, 2000, Pages 48-54

  Korzets, A ^b   Ori, Y ^b   Chagnac, A ^b   Weinstein, T ^b   Herman, M ^b   Zevin, D ^b   Malachi, T ^b   Gafter, U ^a  

^a HASHARON HOSPITAL   (Israel)

^b NONE

Author keywords

Erythropoietin; Folic acid; Hemodialysis; Homocysteine

Indexed keywords

FOLIC ACID; HOMOCYSTEINE; RECOMBINANT ERYTHROPOIETIN;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIET SUPPLEMENTATION; DRUG EFFECT; ERYTHROPOIESIS; FEMALE; FOLIC ACID DEFICIENCY; HEMODIALYSIS; HUMAN; HYPERHOMOCYSTEINEMIA; MALE; RANDOMIZED CONTROLLED TRIAL;

ANALYSIS OF VARIANCE; CASE-CONTROL STUDIES; CROSS-SECTIONAL STUDIES; ERYTHROPOIETIN; ERYTHROPOIETIN, RECOMBINANT; FEMALE; FOLIC ACID; FOLIC ACID DEFICIENCY; HUMANS; HYPERHOMOCYSTEINEMIA; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; RENAL DIALYSIS;

EID: 0033955604     PISSN: 03010430     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (41)

1. Araki A, Sako Y 1987 Determination of free and total homocysteine in human plasma by high performance chromatography with fluorescence detection. J Chromatomogr 422: 43-32
2. Aranadottir M, Brattstrom L, Simonson O, Thysell H, Hulberg B, Andersson A, Nilsson-Ehle P 1993 The effect of high dose pyridoxine and folic acid supplementation on serum lipid and plasma homocysteine concentrations in dialysis patients. Clin Nephrol 40: 236-240
3. Bachmann J, Tepel M, Raidt H, Reizler R, Graefe U, Langer K, Zidek W 1995 Hyperhomocysteinemia and risk for vascular disease in hemodialysis patients. J Am Soc Nephrol 6: 121-125
4. Bamonti-Catena F, Buccuabtu G, Porcella A, Valenti G, Como G, Finazzi S, Maiolo AT 1999 Folate measurements in patients on regular hemodialysis treatment. Am J Kidney Dis 33: 492-497
5. Bode-Boger SM, Boger RH, Kuhn M, Rademacher J, Frolich JC 1996 Recombinant human erythropoietin enhances vasoconstrictor tone via endothelin-1 and constrictor prostanoids. Kidney Int 50: 1255-1261
6. Bostom AG, Shemin D, Lapane KL, Hume AL, Yoburn D, Nadeau MR, Bendich A, Selhub J, Roenberg IH 1996 High-dose B vitamin treatment of hyperhomocysteinemia in dialysis patients. Kidney Int 49: 147-152
7. Bostom AG, Lathrop L 1997 Hyperhomocysteinemia in end-stage renal disease: prevalence, etiology and potential relationship to arteriosclerotic outcomes. Kidney Int 52: 10-20
8. Brattstrom LE, Israelsson B, Jeppsson JO, Hultberg BL 1988 Folic acid - an innocuous means to reduce plasma homocysteine. Scand J Clin Lab Invest 48: 215-221
9. Carlini RG, Dusso AS, Obialo CI, Alverez UM, Rothstein M 1993 Recombinant human erythropoietin increases endothelin-release by endothelial cells. Kidney Int 43: 1010-1014
10. Chauveau P, Chadefaux B, Coude M, Aupetit J, Hannedouche T, Kamoun P, Jungers P 1993 Hyperhomocysteinemia, a risk factor for artherosclerosis in chronic uremic patients. Kidney Int 43 (Suppl 41): S72-S77
11. Chauveau P, Chadofaux H, Coude M, Aupetit J, Kamoun P, Jungers P 1996 Long-term folic acid (but not pyridoxine) supplementation lowers elevated plasma homocysteine levels in chronic renal failure. Miner Electrolyte Metab 22: 106-109
12. Clarke R, Daly L, Robinson K, Naughten H, Cahalane S, Fowler B, Graham I 1991 Hyperhomocysteinemia: an independent risk factor for vascular disease. N Engl J Med 324: 1149-1155
13. Cunningham J, Sharman VL, Goodwill FJ, Marsh FP 1981 Do patients receiving haemodialysis need folic acid supplements? BMJ 282: 1582
14. Dennis VW, Robinson K 1996 Homocysteinemia and vascular disease in end-stage renal failure. Kidney Int 50 (Suppl 57): S11-S17
15. Dierkes J, Dourose U, Aubrosch A, Bosselmann HP, Neumann KH, Lyley C 1999 Response of hyperhomocysteinemia to folic acid supplementation in patients with end-stage renal disease. Clin Nephrol 51: 108-115
16. Edmunds ME, Devoy M, Tomson CRV, Krishna U, Clayworth A, Durrant ST, Feehally J, Walls J 1991 Plasma erythropoietin levels and acquired cystic disease of the kidney in patients receiving regular hemodialysis treatment. Br J Haematol 78: 275-277
17. Hampers CL Steiff R, Nathan DG, Synder D, Merrill JP 1967 Megaloblastic hematopoiesis in uremia and in patients on long-term hemodialysis. N Engl J Med 276: 551-554
18. 12 and folic acid in end-stage renal disease following low-dose supplementation with folic acid. Am J Nephrol 18: 367-372
19. Janssen MJ, van Guldener C, de Jong GM, van der Berg M, Stehouwer CD, Donker AJ 1996 Folic acid treatment of hyperhomocysteinemia in dialysis patients. Miner Electrolyte Metab 22: 110-114
20. Kang S, Wong PWK, Bidani A, Milanez S 1983 Plasma protein-bound homocysteine in patients requiring chronic haemodialysis. Clin Sci 65: 335-336
21. Kong S, Wong PWK, Norusis M 1987 Homocysteinemia due to folate deficiency. Metabolism 36: 458-462
22. 12 supplementation necessary in chronic hemodialysis patients with EPO treatment? Clin Nephrol 42: 343-344
23. Lash J, Smith EC 1990 Is folate supplementation necessary in dialysis patients? Int J Artif Organs 13: 785-786
24. Lentz SK, Sadler JE 1991 Inhibition of thrombomodulin surfexpression and protein C activation by the thrombogenic agent homocysteine. J Clin Invest 88: 1906-1914
25. Lewis CA, Pancharuniti N, Sauberlich HE 1992 Plasma folate adequacy as determined by homocysteine level. Ann NY Acad Sci 669: 360-362
26. Mydlik M, Derzsiova K 1996 Vitamins during EPO treatment in hemodialyzed patients. Am J Kidney Dis 27: A10
27. Nagel T, Akizawa T, Nakashima Y, Kohjiro S, Nabeshima K, Kanamoni N, Takayama K, Kinugassa E, Koshikawa S 1995 Effects of rhEPO on cell proliferation and endothelin-1 production in cultured endothelial cells. Nephrol Dial Transplant 10: 1814-1819
28. Ono K, Hisasue Y 1992 Is folate supplementation necessary in haemodialysis patients on erythropoietin therapy? Clin Nephrol 38: 290-292
29. Pronei W, Reigler-Keil M, Silberhauer K, Stockenhuber F 1995 Folic acid supplementation improves erythropoietin response. Nephron 71: 395-400
30. Ramirez G, Chen M, Boyce HW, Fuller SM, Ganguly R, Brueggemeyer CD, Butcher B 1986 Longitudinal follow-up of chronic haemodialysis patients without vitamin supplementation. Kidney Int 30: 99-106
31. Selhub J, Jacques PF, Bostom AG, D'Agostino RB, Wilson PWF, Belanger AJ, O'Leary DH, Wolf PA, Schaefer EJ, Rosenberg IH 1995 Association between homocysteine concentrations and extracranial carotid artery stenosis. N Engl J Med 332: 286-291
32. Sharman VL, Cunningham J, Goodwill FJ, Marsh EP 1982 Do patients receiving regular haemodialysis need folic acid supplements? BMJ 285: 96-97
33. Stamler JS, Osborne JA, Jaraki O, Rabbani LE, Mullins M, Singel D, Loscaro J 1993 Adverse vascular effects of homocysteine are modulated by endothelium-derived relaxing factor and related oxides of oxygen. J Clin Invest 91: 308-318
34. Tamura T, Johnston KE, Bergman SM 1996 Homocysteine and folate concentrations in blood from patients treated with hemodialysis. J Am Soc Nephrol 7: 2414-1418
35. Taylor JE, Belch JJ, MacLaren M, Henderson IS, Stewart WK 199.3 Effect of erythropoietin therapy and withdrawal on blood coagulation and fibrinolysis in haemodialysis patients. Kidney Int 44: 182-190
36. Ueland PM, Refsum H 1989 Plasma homocysteine, a risk factor for vascular disease: plasma levels in health, disease and drug therapy. J Lab Clin Med 114: 473-501
37. Van der Molen, Van der Heuvel LP, te Poele Potoff MT, Monnens LAH, Eskes TK, Blom JH 1996 The effect of folic acid on the homocysteine metabolism in human umbilical vein endothelial cells. Eur J Clin Invest 26: 304-309
38. Westhuyzen J 1998 Folate supplementation in the dialysis patient fragmentary evidence and tentative recommendations. Nephrol Dial Transplant 13: 2748-2750
39. Whitehead VM, County CH, Posen GA, Kaye M 1968 Homeostasis of folic acid in patients undergoing maintenance hemodialysis. N Engl J Med 279: 970-794
40. Wilcken DEL, Dudman NPB, Tyrrell PA, Robertson MR 1988 Folic acid lowers elevated plasma homocysteine in chronic renal insufficiency: possible implications for prevention of vascular disease. Metabolism 37: 697-701
41. Wilcken DEL, Dudham BPB 1989 Mechanisms of thrombogenesis and accelerated atherogenesis in homocysteinaemia. Haemostasis 19 (Suppl 1): 14-23